Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,583 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all
Completed Phase 3 Interventional Results available

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

NCT03302234
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • Burbank, California • Monterey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Type 1 Diabetes

NCT01049412
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
Chula Vista, California • Atlanta, Georgia • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 30, 2026, 4:15 PM EDT
Completed No phase listed Observational

Clinical Evaluation of BD NEXT Pen Needle

NCT01852136
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
BD NEXT 31G x 5 mm pen needle, BD NEXT 31G x 8mm pen needle, BD NEXT 32G x 4mm pen needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
35 Years to 80 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Toms River, New Jersey • Asheville, North Carolina • Kingsport, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 4:15 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

NCT02229175
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

NCT00211510
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
7
States / cities
Los Angeles, California • Stanford, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 30, 2026, 4:15 PM EDT
Active, not recruiting Not applicable Interventional

AIDANET Pediatrics

NCT07020936
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Normal Glycemia Goal, Tight Glycemia Goal
Device
Lead sponsor
Mark D. DeBoer, MD, MSc., MCR
Other
Eligibility
6 Years to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Completed No phase listed Observational

Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes

NCT03435198
View directory record Official record
Conditions
Volatile Organic Compounds, Hypoglycemia, Type 1 Diabetes Mellitus
Interventions
Collect exhaled breath during low and normal blood sugar
Diagnostic Test
Lead sponsor
East Tennessee State University
Other
Eligibility
5 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 4:15 PM EDT
Approved For Marketing No phase listed Expanded access

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT03791567
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Donislecel (allogeneic islets of Langerhans for transplant)
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

NCT01831765
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
116
States / cities
Mobile, Alabama • Tucson, Arizona • Anaheim, California + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

NCT01176253
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood draw
Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Duarte, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

NCT03554486
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Fiasp, Novolog
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

NCT02971202
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions
Hyperinsulinemic, euglycemic clamp, 20% dextrose
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years to 51 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 30, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional

Utilizing Community Health Workers as Diabetes Technology Coaches for Children With Type 1 Diabetes Using Automated Insulin Delivery

NCT07154251
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Community Health Worker
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 30, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

NCT04524949
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IMCY-0098 450 μg, IMCY-0098 1350 μg, Placebo
Drug
Lead sponsor
Imcyse SA
Industry
Eligibility
18 Years to 44 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

NCT04157738
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes
Interventions
Rapid-Acting Insulin, Long acting insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
7 Years to 15 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Recruiting Phase 3 Interventional

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

NCT05819138
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Early Phase 1 Interventional

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

NCT01472406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sansum Closed-Loop Artificial Pancreas, Insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, Safety Health Monitoring System
Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2021 · Synced Oct 30, 2026, 4:15 PM EDT
Completed No phase listed Observational

Impact of Hybrid Closed-Loop Systems on Sleep and Psychosocial Outcomes in Youth With T1D and Their Parents

NCT04431947
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 17 Years
Enrollment
46 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 30, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

NCT01464099
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 30, 2026, 4:15 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

T and B Cell Responses in Autoimmune Diseases

NCT01947036
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 30, 2026, 4:15 PM EDT